- 促效剂标靶和并用 -
While much attention in immunotherapy to-date has been given to checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4, there’s a rising interest in agonist targets such as OX40, 4-1BB, CD27, GITR, ICOS, TNFR receptors, STING, etc., as it’s been found that antagonists alone are not enough to elicit response in the majority of patients.

PEGS Europe’s Inaugural Agonist Immunotherapy Targets and Combination Therapies presents updates and exciting development of these co-stimulatory agonists in monotherapy or in combination with co-inhibitory antagonists.


Preliminary Agenda

OX40 AND 4-1BB AGONISTS

KEYNOTE PRESENTATION: Deciphering 4-1BB (CD137) for Cancer Immunotherapy
Ignacio Melero, MD, PhD, Professor, Immunology & Immunotherapy, University of Navarra

ATOR-1017 – An Agonistic Tumor Directed Fcγ-Receptor Cross Linking Dependent CD137 Antibody
Anna Säll, PhD, Scientist, Alligator Bioscience

Multispecific and Multivalent Antibodies as OX40 Agonists
Francis Qufei Li, PhD, Principal Scientist, R&D, Invenra, Inc.

Tumor-Targeted DARPin® Drug Candidates for Tumor-Restricted Immune Cell Co-Activation
Christian Reichen, PhD, Senior Scientist Lead Generation, Protein Engineering, Molecular Partners AG

CYTOKINE RECEPTORS – IL2, TNFR-SF

Interleukin-2: Releasing an Immune System Brake to Attack Tumors
Daniel Christ, PhD, Associate Professor, Director, Centre for Targeted Therapy, Garvan Institute of Medical Research 

NKTR-214: Cytokine Engineering to Access the IL-2 Pathway
Jonathan Zalevsky, PhD, SVP Research, CSO, Nektar Therapeutics

AcTakines: A Novel Class of Cancer Immunotherapeutics
Erik Depla, PhD, Director, Biology, Orionis Biosciences

Agonistic Activation of TNFR-SF Receptors by HexaBody IgG-induced Oligomerization
Rob de Jong, PhD, Assistant Director, Protein Chemistry & CMC, Genmab BV

HERA: Engineering Next-Generation TNFR-SF Agonists for Cancer Immunotherapy
Oliver Hill, PhD, Vice President, Molecular Biology/Protein Engineering, Apogenix AG

COMBINATION THERAPIES

Chemotherapy Combinations to Enhance Tumor Response to Agonist Antibodies
Allison Betof Warner, MD, PhD, Medical Oncology Fellow, Memorial Sloan Kettering Cancer Center

GITR and OX40 Agonist Antibody Design and Combination Approaches
Patrick Mayes, PhD, Executive Director, Head, Antibody Research, Incyte

Tumor-Targeted Combination of TNFSF Agonists and IL-15 for Cancer Immunotherapy
Dafne Muller, PhD, Group Leader, Institute of Cell Biology and Immunology, University of Stuttgart

Oncorus Oncolytic HSV as a Platform for Combination Immunotherapy
Christophe Queva, PhD, CSO, Oncorus


* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English